<p>加拿大温哥华，2025 年 12 月 31 日（GLOBE NEWSWIRE）-- Clearmind Medicine Inc.（纳斯达克代码：CMND），（法兰克福证券交易所代码：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。公司宣布已收到纳斯达克证券市场（“纳斯达克”）上市资格部门的通知信，告知公司已重新符合纳斯达克上市规则 5550(a)(2) 中规定的最低出价价格要求。</p>
<p>公司此前已宣布，2025 年 12 月 4 日收到纳斯达克的通知，称其未符合纳斯达克上市规则 5550(a)(2) 中规定的最低出价价格要求，因为公司普通股的收盘出价在连续 30 个交易日内低于 1.00 美元。</p>
<p>2025 年 12 月 30 日，纳斯达克向公司确认，在 2025 年 12 月 15 日至 12 月 29 日的最后 10 个连续交易日内，公司普通股的收盘出价为每股 1.00 美元或更高，因此公司已重新符合上市规则 5550(a)(2)，该事项现已结束。</p>
<p><strong>关于 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家临床阶段的迷幻药物生物技术公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分关注的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
<p>公司的知识产权组合目前包括十九个专利系列，涵盖 31 项已授予专利。公司打算在必要时为其化合物申请更多专利，并将对获取额外知识产权持开放态度，以扩展其组合。</p>
<p>Clearmind 的股票在纳斯达克以 “CMND” 符号交易，在法兰克福证券交易所以 “CWY0” 符号交易。</p>
<p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
<p>投资者关系</p>
<p>invest@clearmindmedicine.com</p>
<p>电话：（604）260-1566</p>
<p>美国：CMND@crescendo-ir.com</p>
<p>一般咨询</p>
<p>Info@Clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法所定义的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达的变体旨在识别前瞻性声明。例如，当公司讨论推进针对 AUD 的创新治疗、来自患者和领先临床机构对 CMND-100 的高度关注、CMND-100 转变 AUD 治疗的潜力以及其相信这一快速进展使其能够生成额外有价值的数据，从而更接近提供解决成瘾根本原因的突破性疗法并改善安全性时，公司正在使用前瞻性声明。前瞻性声明不是历史事实，而是基于管理层当前的期望、信念和预测，这些预测本质上具有不确定性。这些期望、信念和预测是以善意表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或暗示的内容有重大差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的年度报告（表格 20-F）及其后续向 SEC 提交的文件。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接仅为方便，网站上包含的信息不被纳入本新闻稿。Clearmind 对第三方网站的内容不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EVTVNeU0zTXpRd09ERXhJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EVTVNeU0zTXpRd09ERXhJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

<p>Clearmind Medicine Inc. 已经重新符合纳斯达克的最低股价要求，因为其股价在连续 10 个交易日内收盘价达到或超过 1.00 美元。此前，该公司因股价在超过 30 天内低于 1.00 美元而收到不合规通知。Clearmind 专注于开发源自迷幻药的治疗方法，以应对未得到充分治疗的健康问题，包括酒精使用障碍，并持有 31 项已授予的专利组合</p>

<p>Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).</p>
<div class="lb-trans"><p>加拿大温哥华，2025 年 12 月 31 日（GLOBE NEWSWIRE）-- Clearmind Medicine Inc.（纳斯达克代码：CMND），（法兰克福证券交易所代码：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。公司宣布已收到纳斯达克证券市场（“纳斯达克”）上市资格部门的通知信，告知公司已重新符合纳斯达克上市规则 5550(a)(2) 中规定的最低出价价格要求。</p>
</div><p>The Company had previously announced that it was notified by Nasdaq on December 4, 2025, that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s common shares had been below $1.00 for more than 30 consecutive business days.</p>
<div class="lb-trans"><p>公司此前已宣布，2025 年 12 月 4 日收到纳斯达克的通知，称其未符合纳斯达克上市规则 5550(a)(2) 中规定的最低出价价格要求，因为公司普通股的收盘出价在连续 30 个交易日内低于 1.00 美元。</p>
</div><p>On December 30, 2025, Nasdaq provided confirmation to the Company that for the last 10 consecutive business days, from December 15 through December 29, 2025, the closing bid price of the Company’s common shares was $1.00 per share or greater, that the Company has hence regained compliance with Listing Rule 5550(a)(2) and that the matter is now closed.</p>
<div class="lb-trans"><p>2025 年 12 月 30 日，纳斯达克向公司确认，在 2025 年 12 月 15 日至 12 月 29 日的最后 10 个连续交易日内，公司普通股的收盘出价为每股 1.00 美元或更高，因此公司已重新符合上市规则 5550(a)(2)，该事项现已结束。</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家临床阶段的迷幻药物生物技术公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分关注的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知识产权组合目前包括十九个专利系列，涵盖 31 项已授予专利。公司打算在必要时为其化合物申请更多专利，并将对获取额外知识产权持开放态度，以扩展其组合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND&#34; and the Frankfurt Stock Exchange under the symbol “CWY0.”</p>
<div class="lb-trans"><p>Clearmind 的股票在纳斯达克以 “CMND” 符号交易，在法兰克福证券交易所以 “CWY0” 符号交易。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>Telephone: (604) 260-1566</p>
<div class="lb-trans"><p>电话：（604）260-1566</p>
</div><p>US: CMND@crescendo-ir.com</p>
<div class="lb-trans"><p>美国：CMND@crescendo-ir.com</p>
</div><p>General Inquiries</p>
<div class="lb-trans"><p>一般咨询</p>
</div><p>Info@Clearmindmedicine.com</p>
<div class="lb-trans"><p>Info@Clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing innovative treatments for AUD, the high level of interest from both patients and leading clinical sites in CMND-100, CMND-100’s potential to transform AUD treatment and its belief that that this rapid progress positions it to generate additional valuable data, bringing it closer to delivering a breakthrough therapy that addresses the root causes of addiction with an improved safety profile. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法所定义的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达的变体旨在识别前瞻性声明。例如，当公司讨论推进针对 AUD 的创新治疗、来自患者和领先临床机构对 CMND-100 的高度关注、CMND-100 转变 AUD 治疗的潜力以及其相信这一快速进展使其能够生成额外有价值的数据，从而更接近提供解决成瘾根本原因的突破性疗法并改善安全性时，公司正在使用前瞻性声明。前瞻性声明不是历史事实，而是基于管理层当前的期望、信念和预测，这些预测本质上具有不确定性。这些期望、信念和预测是以善意表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或暗示的内容有重大差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的年度报告（表格 20-F）及其后续向 SEC 提交的文件。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接仅为方便，网站上包含的信息不被纳入本新闻稿。Clearmind 对第三方网站的内容不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EVTVNeU0zTXpRd09ERXhJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODU5MyM3MzQwODExIzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine 重新符合纳斯达克最低出价要求 | CMND 股票新闻